RADNET INC (RDNT)

US7504911022 - Common Stock

73.28  -0.08 (-0.11%)

Fundamental Rating

4

Overall RDNT gets a fundamental rating of 4 out of 10. We evaluated RDNT against 108 industry peers in the Health Care Providers & Services industry. RDNT has an average financial health and profitability rating. RDNT is valued quite expensive, but it does show an excellent growth.



4

1. Profitability

1.1 Basic Checks

In the past year RDNT was profitable.
In the past year RDNT had a positive cash flow from operations.
RDNT had positive earnings in 4 of the past 5 years.
In the past 5 years RDNT always reported a positive cash flow from operatings.

1.2 Ratios

RDNT has a Return On Assets (-0.13%) which is comparable to the rest of the industry.
With a Return On Equity value of -0.49%, RDNT perfoms like the industry average, outperforming 57.01% of the companies in the same industry.
RDNT has a Return On Invested Capital (3.14%) which is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for RDNT is below the industry average of 8.15%.
Industry RankSector Rank
ROA -0.13%
ROE -0.49%
ROIC 3.14%
ROA(3y)0.58%
ROA(5y)0.36%
ROE(3y)4.83%
ROE(5y)3.06%
ROIC(3y)3.25%
ROIC(5y)3.04%

1.3 Margins

RDNT's Profit Margin has declined in the last couple of years.
RDNT's Operating Margin of 6.36% is fine compared to the rest of the industry. RDNT outperforms 69.16% of its industry peers.
In the last couple of years the Operating Margin of RDNT has grown nicely.
With a Gross Margin value of 23.38%, RDNT perfoms like the industry average, outperforming 48.60% of the companies in the same industry.
RDNT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.36%
PM (TTM) N/A
GM 23.38%
OM growth 3Y49.86%
OM growth 5Y11%
PM growth 3YN/A
PM growth 5Y-43.61%
GM growth 3Y2.03%
GM growth 5Y0.93%

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RDNT is destroying value.
The number of shares outstanding for RDNT has been increased compared to 1 year ago.
RDNT has more shares outstanding than it did 5 years ago.
RDNT has a better debt/assets ratio than last year.

2.2 Solvency

RDNT has an Altman-Z score of 2.19. This is not the best score and indicates that RDNT is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.19, RDNT is in line with its industry, outperforming 53.27% of the companies in the same industry.
The Debt to FCF ratio of RDNT is 10.83, which is on the high side as it means it would take RDNT, 10.83 years of fcf income to pay off all of its debts.
RDNT has a Debt to FCF ratio (10.83) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.11 is on the high side and indicates that RDNT has dependencies on debt financing.
RDNT has a Debt to Equity ratio of 1.11. This is in the lower half of the industry: RDNT underperforms 66.36% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF 10.83
Altman-Z 2.19
ROIC/WACC0.36
WACC8.8%

2.3 Liquidity

A Current Ratio of 2.16 indicates that RDNT has no problem at all paying its short term obligations.
The Current ratio of RDNT (2.16) is better than 75.70% of its industry peers.
RDNT has a Quick Ratio of 2.16. This indicates that RDNT is financially healthy and has no problem in meeting its short term obligations.
RDNT has a Quick ratio of 2.16. This is in the better half of the industry: RDNT outperforms 76.64% of its industry peers.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 2.16

7

3. Growth

3.1 Past

RDNT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.59%, which is quite impressive.
RDNT shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.73% yearly.
RDNT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.20%.
The Revenue has been growing by 10.64% on average over the past years. This is quite good.
EPS 1Y (TTM)36.59%
EPS 3YN/A
EPS 5Y2.73%
EPS Q2Q%-7.14%
Revenue 1Y (TTM)12.2%
Revenue growth 3Y14.68%
Revenue growth 5Y10.64%
Sales Q2Q%14.72%

3.2 Future

RDNT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.68% yearly.
Based on estimates for the next years, RDNT will show a quite strong growth in Revenue. The Revenue will grow by 10.06% on average per year.
EPS Next Y33.96%
EPS Next 2Y22.87%
EPS Next 3Y24.68%
EPS Next 5YN/A
Revenue Next Year13.43%
Revenue Next 2Y11.11%
Revenue Next 3Y10.06%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 130.86, RDNT can be considered very expensive at the moment.
RDNT's Price/Earnings ratio is in line with the industry average.
RDNT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.54.
With a Price/Forward Earnings ratio of 97.09, RDNT can be considered very expensive at the moment.
RDNT's Price/Forward Earnings ratio is in line with the industry average.
RDNT is valuated expensively when we compare the Price/Forward Earnings ratio to 23.99, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 130.86
Fwd PE 97.09

4.2 Price Multiples

RDNT's Enterprise Value to EBITDA is on the same level as the industry average.
Based on the Price/Free Cash Flow ratio, RDNT is valued a bit cheaper than 61.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF 57.59
EV/EBITDA 23.06

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
RDNT's earnings are expected to grow with 24.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.85
PEG (5Y)47.93
EPS Next 2Y22.87%
EPS Next 3Y24.68%

0

5. Dividend

5.1 Amount

No dividends for RDNT!.
Industry RankSector Rank
Dividend Yield N/A

RADNET INC

NASDAQ:RDNT (12/26/2024, 10:34:02 AM)

73.28

-0.08 (-0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-10 2024-11-10/amc
Earnings (Next)N/A N/A
Inst Owners85.36%
Inst Owner Change1.44%
Ins Owners11.96%
Ins Owner Change4.36%
Market Cap5.42B
Analysts85
Price Target90.95 (24.11%)
Short Float %5.53%
Short Ratio7.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.15%
Min EPS beat(2)-12.7%
Max EPS beat(2)-5.6%
EPS beat(4)2
Avg EPS beat(4)320.19%
Min EPS beat(4)-12.7%
Max EPS beat(4)1272.55%
EPS beat(8)4
Avg EPS beat(8)189.17%
EPS beat(12)5
Avg EPS beat(12)-250.87%
EPS beat(16)8
Avg EPS beat(16)-169.61%
Revenue beat(2)2
Avg Revenue beat(2)3.01%
Min Revenue beat(2)2.78%
Max Revenue beat(2)3.25%
Revenue beat(4)4
Avg Revenue beat(4)1.72%
Min Revenue beat(4)0.36%
Max Revenue beat(4)3.25%
Revenue beat(8)8
Avg Revenue beat(8)2.54%
Revenue beat(12)9
Avg Revenue beat(12)1.12%
Revenue beat(16)12
Avg Revenue beat(16)0.94%
PT rev (1m)15.3%
PT rev (3m)30.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.11%
EPS NY rev (1m)1.65%
EPS NY rev (3m)1.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.34%
Revenue NY rev (1m)1.86%
Revenue NY rev (3m)1.59%
Valuation
Industry RankSector Rank
PE 130.86
Fwd PE 97.09
P/S 3.06
P/FCF 57.59
P/OCF 19.41
P/B 6.06
P/tB 54.78
EV/EBITDA 23.06
EPS(TTM)0.56
EY0.76%
EPS(NY)0.75
Fwd EY1.03%
FCF(TTM)1.27
FCFY1.74%
OCF(TTM)3.77
OCFY5.15%
SpS23.95
BVpS12.09
TBVpS1.34
PEG (NY)3.85
PEG (5Y)47.93
Profitability
Industry RankSector Rank
ROA -0.13%
ROE -0.49%
ROCE 4.02%
ROIC 3.14%
ROICexc 4.29%
ROICexgc 7%
OM 6.36%
PM (TTM) N/A
GM 23.38%
FCFM 5.31%
ROA(3y)0.58%
ROA(5y)0.36%
ROE(3y)4.83%
ROE(5y)3.06%
ROIC(3y)3.25%
ROIC(5y)3.04%
ROICexc(3y)3.63%
ROICexc(5y)3.31%
ROICexgc(3y)5.98%
ROICexgc(5y)5.43%
ROCE(3y)4.16%
ROCE(5y)3.89%
ROICexcg growth 3Y50.2%
ROICexcg growth 5Y-0.37%
ROICexc growth 3Y50.64%
ROICexc growth 5Y4.68%
OM growth 3Y49.86%
OM growth 5Y11%
PM growth 3YN/A
PM growth 5Y-43.61%
GM growth 3Y2.03%
GM growth 5Y0.93%
F-Score5
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF 10.83
Debt/EBITDA 4.03
Cap/Depr 137.73%
Cap/Sales 10.45%
Interest Coverage 1.99
Cash Conversion 113.01%
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 2.16
Altman-Z 2.19
F-Score5
WACC8.8%
ROIC/WACC0.36
Cap/Depr(3y)129.51%
Cap/Depr(5y)117.82%
Cap/Sales(3y)10.05%
Cap/Sales(5y)9.07%
Profit Quality(3y)577.28%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.59%
EPS 3YN/A
EPS 5Y2.73%
EPS Q2Q%-7.14%
EPS Next Y33.96%
EPS Next 2Y22.87%
EPS Next 3Y24.68%
EPS Next 5YN/A
Revenue 1Y (TTM)12.2%
Revenue growth 3Y14.68%
Revenue growth 5Y10.64%
Sales Q2Q%14.72%
Revenue Next Year13.43%
Revenue Next 2Y11.11%
Revenue Next 3Y10.06%
Revenue Next 5YN/A
EBIT growth 1Y26.16%
EBIT growth 3Y71.86%
EBIT growth 5Y22.81%
EBIT Next Year180.93%
EBIT Next 3Y50.29%
EBIT Next 5YN/A
FCF growth 1Y948.59%
FCF growth 3Y-31.81%
FCF growth 5Y-0.15%
OCF growth 1Y96.8%
OCF growth 3Y-1.88%
OCF growth 5Y13.59%